Orkambi® was approved by the FDA in 2015. Orkambi® is an ion channel modulator for the treatment of cystic fibrosis (CF) in patients who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ion channel modulators aim to correct the cellular defect that causes CF rather than the severity of the symptoms caused by the disease. Orkambi® is a tablet that is taken orally. Maxor has partnered with Vertex as a Limited Distribution Pharmacy for Orkambi®.
Orkambi® Guidance & Patient Support
Vertex GPS™ : Guidance & Patient Support is a program created by Vertex Pharmaceuticals to assist patients in the navigation of life with Cystic Fibrosis. Vertex GPS™ Case Managers are available to help provide information about reimbursement support, potential financial assistance, and disease and treatment information while a patient is on Orkambi.